334,197 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by Voloridge Investment Management LLC

Voloridge Investment Management LLC bought a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 334,197 shares of the company's stock, valued at approximately $54,451,000. Voloridge Investment Management LLC owned about 0.07% of Zoetis as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Mission Wealth Management LP boosted its holdings in Zoetis by 2.0% in the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock worth $479,000 after purchasing an additional 59 shares in the last quarter. VeraBank N.A. boosted its stake in shares of Zoetis by 4.1% during the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company's stock worth $254,000 after acquiring an additional 62 shares in the last quarter. HUB Investment Partners LLC boosted its stake in shares of Zoetis by 4.7% during the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock worth $224,000 after acquiring an additional 62 shares in the last quarter. Coppell Advisory Solutions LLC increased its holdings in shares of Zoetis by 18.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock valued at $68,000 after acquiring an additional 64 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators raised its stake in shares of Zoetis by 6.6% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company's stock valued at $170,000 after acquiring an additional 65 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Trading Down 0.2%

Shares of ZTS opened at $163.63 on Wednesday. The stock's 50-day moving average price is $156.58 and its 200 day moving average price is $165.08. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The firm has a market capitalization of $72.85 billion, a price-to-earnings ratio of 29.91, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. The company had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Zoetis's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.38 EPS. As a group, research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ZTS shares. Piper Sandler boosted their target price on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Monday, May 12th. Morgan Stanley reduced their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Barclays raised their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Finally, UBS Group decreased their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $212.75.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $170.00, for a total value of $55,420.00. Following the completion of the transaction, the executive vice president now owns 15,781 shares of the company's stock, valued at $2,682,770. This represents a 2.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the firm's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. This represents a 9.71% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.18% of the company's stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.